Winston  Kung net worth and biography

Winston Kung Biography and Net Worth

Prior to joining PMV Pharma, Mr. Kung was a Vice President of Business Development and Global Alliances at Celgene and Chief Business Officer at Celgene Cellular Therapeutics (CCT). Over four and a half years, he led the formation of a strategic long range plan for CCT, multiple transactions and a team that managed Celgene’s alliance portfolio of over 100 collaborations, equity investments and company integrations. Prior to Celgene, Mr. Kung worked from 2007 to 2013 at Citigroup in its Global Healthcare Investment Banking group and Lehman Brothers (which was subsequently acquired by Barclays) in its Global Mergers and Acquisition Group. He worked on various transactions including public and private financings, mergers, acquisitions, spin-outs and other financial advisory engagements.

From 2004 to 2007, he served at Amgen as a co-founder of the Alliance Management group, and also served as the deal lead on multiple acquisitions as part of the Corporate Development group. Mr. Kung was also part of the Business and Corporate Development group at Genentech. He worked on several transactions, including leading the spin-out of Tercica (acquired by Ipsen), and co- led the formation of the Genenfund, Genentech’s first Corporate Venture Capital Fund. He received his MBA from Harvard Business School, and his A.B. in Biology and A.B in International Relations with honors from Brown University.

What is Winston Kung's net worth?

The estimated net worth of Winston Kung is at least $10,431.00 as of August 3rd, 2021. Mr. Kung owns 6,100 shares of PMV Pharmaceuticals stock worth more than $10,431 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Kung may own. Learn More about Winston Kung's net worth.

How do I contact Winston Kung?

The corporate mailing address for Mr. Kung and other PMV Pharmaceuticals executives is , , . PMV Pharmaceuticals can also be reached via phone at 609-642-6670 and via email at [email protected]. Learn More on Winston Kung's contact information.

Has Winston Kung been buying or selling shares of PMV Pharmaceuticals?

Winston Kung has not been actively trading shares of PMV Pharmaceuticals within the last three months. Most recently, Winston Kung sold 4,500 shares of the business's stock in a transaction on Tuesday, August 3rd. The shares were sold at an average price of $33.82, for a transaction totalling $152,190.00. Following the completion of the sale, the chief financial officer now directly owns 6,100 shares of the company's stock, valued at $206,302. Learn More on Winston Kung's trading history.

Who are PMV Pharmaceuticals' active insiders?

PMV Pharmaceuticals' insider roster includes Leila Alland (Insider), Richard Heyman (Director), Winston Kung (CFO), Arnold Levine (Director), David Mack (CEO), and Thilo Schroeder (Director). Learn More on PMV Pharmaceuticals' active insiders.

Are insiders buying or selling shares of PMV Pharmaceuticals?

During the last twelve months, insiders at the sold shares 2 times. They sold a total of 91,890 shares worth more than $222,931.26. The most recent insider tranaction occured on November, 22nd when Major Shareholder Orbimed Advisors Llc sold 87,786 shares worth more than $195,762.78. Insiders at PMV Pharmaceuticals own 7.6% of the company. Learn More about insider trades at PMV Pharmaceuticals.

Information on this page was last updated on 11/22/2023.

Winston Kung Insider Trading History at PMV Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/3/2021Sell4,500$33.82$152,190.006,100View SEC Filing Icon  
7/8/2021Sell4,500$33.75$151,875.00View SEC Filing Icon  
6/4/2021Sell4,500$33.75$151,875.006,100View SEC Filing Icon  
5/3/2021Sell4,500$33.75$151,875.006,100View SEC Filing Icon  
See Full Table

Winston Kung Buying and Selling Activity at PMV Pharmaceuticals

This chart shows Winston Kung's buying and selling at PMV Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PMV Pharmaceuticals Company Overview

PMV Pharmaceuticals logo
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Read More

Today's Range

Now: $1.73
Low: $1.69
High: $1.77

50 Day Range

MA: $1.69
Low: $1.51
High: $1.93

2 Week Range

Now: $1.73
Low: $1.18
High: $9.72

Volume

285,421 shs

Average Volume

535,438 shs

Market Capitalization

$88.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65